English

GENEREX BIOTECHNOLOGY CORP

EDGAR

GNBT Quarterly report (10-Q) · filed 2021-06-21

139 filing records in this dataset, filed from 1999-03-26 to 2021-06-21. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

20.7 thousand USD

2021 Q3 · USD

Exact inputs and evidence

Revenue: 20695 USD Source

Operating margin

-30,748.76%

2021 Q3 · %

Exact inputs and evidence

Operating Income: -6363455 USD Source
Revenue: 20695 USD Source

Operating cash flow

577 thousand USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -1739029 USD Source
Operating Cash Flow: -2315721 USD Source

Free cash flow

577 thousand USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -1739029 USD Source
Operating Cash Flow: -2315721 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 1.68 million USD 2021-04-30 Source
Exact value

1675027 USD
Long-term debt including current maturities: 618 thousand USD 2013-07-31 Source
Exact value

617665 USD
Shares outstanding: 116 million shares 2021-04-30 Source
Exact value

116278690 shares

Reported share-count change

45.46% · 36.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

79936996 shares · 2020-04-30· Source
116278690 shares · 2021-04-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

693 thousand USD

2020-05-01 – 2021-04-30

Exact inputs and evidence

Revenue: 2661396 USD · 2019-08-01 – 2020-07-31 Source
Revenue: 2077764 USD · 2019-08-01 – 2020-04-30 Source
Revenue: 88435 USD · 2020-08-01 – 2020-10-31 Source
Revenue: 0 USD · 2020-11-01 – 2021-01-31 Source
Revenue: 20695 USD · 2021-02-01 – 2021-04-30 Source

Net income

-38.8 million USD

2020-05-01 – 2021-04-30

Exact inputs and evidence

Net income: -34232093 USD · 2019-08-01 – 2020-07-31 Source
Net income: -22353394 USD · 2019-08-01 – 2020-04-30 Source
Net income: -10989076 USD · 2020-08-01 – 2020-10-31 Source
Net income: -24406621 USD · 2020-11-01 – 2021-01-31 Source
Net income: 8485335 USD · 2021-02-01 – 2021-04-30 Source

Capital expenditure

0 USD

2020-05-01 – 2021-04-30

Exact inputs and evidence

Capital expenditure: 4616 USD · 2019-08-01 – 2020-07-31 Source
Capital expenditure: 4616 USD · 2019-08-01 – 2020-04-30 Source
Capital expenditure: 0 USD · 2020-08-01 – 2020-10-31 Source
Capital expenditure: 0 USD · 2020-08-01 – 2021-01-31 Source
Capital expenditure: 0 USD · 2020-08-01 – 2020-10-31 Source
Capital expenditure: 0 USD · 2020-08-01 – 2021-04-30 Source
Capital expenditure: 0 USD · 2020-08-01 – 2021-01-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-06-21.

Financial data available through: 2020-07-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2020-07-31
Operating income: 11 of 11 periods available· newest 2020-07-31
Net income: 11 of 11 periods available· newest 2020-07-31
Operating cash flow: 11 of 11 periods available· newest 2020-07-31
Capital expenditure: 6 of 11 periods available· newest 2020-07-31
Total assets: 5 of 11 periods available· newest 2020-07-31
Total liabilities: 5 of 11 periods available· newest 2020-07-31
Current assets: 5 of 11 periods available· newest 2020-07-31
Current liabilities: 5 of 11 periods available· newest 2020-07-31
Cash and cash equivalents: 5 of 11 periods available· newest 2020-07-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2011-07-31
Shares outstanding: 5 of 11 periods available· newest 2020-07-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-57.1%

Prior period

USD 6.2 million

2018-08-01 – 2019-07-31
Current period

USD 2.66 million

2019-08-01 – 2020-07-31

Exact inputs and evidence

2661396 − 6203761 = -3542365 USD

6203761 USD · 2018-08-01 – 2019-07-31
Inspect prior input Prior source
2661396 USD · 2019-08-01 – 2020-07-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Year-over-year change in Revenue: -3542365 USD Concept: fundies:Revenue Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2661396 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#607008 Filing: 000160706220000327 Input fundies:Revenue: 6203761 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#607164 Filing: 000160706220000327
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 23.23 million

Prior period

−USD 11.01 million

2018-08-01 – 2019-07-31
Current period

−USD 34.23 million

2019-08-01 – 2020-07-31

Exact inputs and evidence

-34232093 − -11006794 = -23225299 USD

-11006794 USD · 2018-08-01 – 2019-07-31
Inspect prior input Prior source
-34232093 USD · 2019-08-01 – 2020-07-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Year-over-year change in Net income: -23225299 USD Concept: fundies:NetIncome Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -34232093 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#215550 Filing: 000160706220000327 Input fundies:NetIncome: -11006794 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#215678 Filing: 000160706220000327
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3.45 million

Prior period

−USD 9.57 million

2018-08-01 – 2019-07-31
Current period

−USD 6.12 million

2019-08-01 – 2020-07-31

Exact inputs and evidence

-6121259 − -9574193 = 3452934 USD

-9574193 USD · 2018-08-01 – 2019-07-31
Inspect prior input Prior source
-6121259 USD · 2019-08-01 – 2020-07-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Year-over-year change in Operating cash flow: 3452934 USD Concept: fundies:OperatingCashFlow Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -6121259 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#610399 Filing: 000160706220000327 Input fundies:OperatingCashFlow: -9574193 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#610584 Filing: 000160706220000327
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-98.4%

Prior period

USD 289,917

2018-08-01 – 2019-07-31
Current period

USD 4,616

2019-08-01 – 2020-07-31

Exact inputs and evidence

4616 − 289917 = -285301 USD

289917 USD · 2018-08-01 – 2019-07-31
Inspect prior input Prior source
4616 USD · 2019-08-01 – 2020-07-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Year-over-year change in Capital expenditure: -285301 USD Concept: fundies:CapitalExpenditure Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4616 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#620337 Filing: 000160706220000327 Input fundies:CapitalExpenditure: 289917 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#620518 Filing: 000160706220000327
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2019-08-01 – 2020-07-31

Revenue USD 2.66 million 100% of revenue
Cost of revenue USD 579,857 22% of revenue
Operating expenses USD 20.02 million 752% of revenue
Operating income −USD 17.94 million −674% of revenue
Tax, interest and other Derived USD 16.29 million 612% of revenue
Net income −USD 34.23 million −1,286% of revenue

Cash

Operating cash flow −USD 6.12 million −230% of revenue
Capital expenditure USD 4,616 0.2% of revenue
Free cash flow Derived −USD 6.13 million −230% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2011 Operating loss: operating costs were 2,192% of revenue.
2018 Operating loss: operating costs were 77,030% of revenue.
2019 Operating loss: operating costs were 492% of revenue.
2020 Operating loss: operating costs were 774% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2011 2010-08-01 – 2011-07-31	1172611	25705693 Derived	-24533082	-2857215 Derived	-21675867	-16983751 Derived	Source 2010-08-01 – 2011-07-31: 1172611 USD Inspect Revenue Open source 2010-08-01 – 2011-07-31: -24533082 USD Inspect Operating Income Open source 2010-08-01 – 2011-07-31: -21675867 USD Inspect Net Income Open source 2010-08-01 – 2011-07-31: -16931368 USD Inspect Operating Cash Flow Open source 2010-08-01 – 2011-07-31: 52383 USD Inspect Capital Expenditure Open source
2018 2017-08-01 – 2018-07-31	3244	2498853 Derived	-2495609	-38444307 Derived	35948698	-2301766 Derived	Source 2017-08-01 – 2018-07-31: 3244 USD Inspect Revenue Open source 2017-08-01 – 2018-07-31: -2495609 USD Inspect Operating Income Open source 2017-08-01 – 2018-07-31: 35948698 USD Inspect Net Income Open source 2017-08-01 – 2018-07-31: -2293214 USD Inspect Operating Cash Flow Open source 2017-08-01 – 2018-07-31: 8552 USD Inspect Capital Expenditure Open source
2019 2018-08-01 – 2019-07-31	6203761	30549202 Derived	-24345441	-13338647 Derived	-11006794	-9864110 Derived	Source 2018-08-01 – 2019-07-31: 6203761 USD Inspect Revenue Open source 2018-08-01 – 2019-07-31: -24345441 USD Inspect Operating Income Open source 2018-08-01 – 2019-07-31: -11006794 USD Inspect Net Income Open source 2018-08-01 – 2019-07-31: -9574193 USD Inspect Operating Cash Flow Open source 2018-08-01 – 2019-07-31: 289917 USD Inspect Capital Expenditure Open source
2020 2019-08-01 – 2020-07-31	2661396	20598606 Derived	-17937210	16294883 Derived	-34232093	-6125875 Derived	Source 2019-08-01 – 2020-07-31: 2661396 USD Inspect Revenue Open source 2019-08-01 – 2020-07-31: -17937210 USD Inspect Operating Income Open source 2019-08-01 – 2020-07-31: -34232093 USD Inspect Net Income Open source 2019-08-01 – 2020-07-31: -6121259 USD Inspect Operating Cash Flow Open source 2019-08-01 – 2020-07-31: 4616 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.7M 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-07-31	Revenue	1118509	Revenue: 1118509 Open source
20112011-07-31	Revenue	1172611	Revenue: 1172611 Open source
20182018-07-31	Revenue	3244	Revenue: 3244 Open source
20192019-07-31	Revenue	6203761	Revenue: 6203761 Open source
20202020-07-31	Revenue	2661396	Revenue: 2661396 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-57.1% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-07-31	Year over year	No prior comparable period	Revenue: 1118509 Open source
20112011-07-31	Year over year	4.8%	Revenue: 1172611 Open source Revenue: 1118509 Open source
20182018-07-31	Year over year	No prior comparable period	Revenue: 3244 Open source
20192019-07-31	Year over year	191,138%	Revenue: 6203761 Open source Revenue: 3244 Open source
20202020-07-31	Year over year	-57.1%	Revenue: 2661396 Open source Revenue: 6203761 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -674% 2020

Net margin -1,286.2% 2020

Free cash flow margin -230.2% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20102010-07-31	Operating margin	-2,631.2%	Operating Income: -29429817 Open source Revenue: 1118509 Open source
20112011-07-31	Operating margin	-2,092.2%	Operating Income: -24533082 Open source Revenue: 1172611 Open source
20182018-07-31	Operating margin	-76,930%	Operating Income: -2495609 Open source Revenue: 3244 Open source
20192019-07-31	Operating margin	-392.4%	Operating Income: -24345441 Open source Revenue: 6203761 Open source
20202020-07-31	Operating margin	-674%	Operating Income: -17937210 Open source Revenue: 2661396 Open source
20102010-07-31	Net margin	-2,260.1%	Net Income: -25279940 Open source Revenue: 1118509 Open source
20112011-07-31	Net margin	-1,848.5%	Net Income: -21675867 Open source Revenue: 1172611 Open source
20182018-07-31	Net margin	1,108,159.6%	Net Income: 35948698 Open source Revenue: 3244 Open source
20192019-07-31	Net margin	-177.4%	Net Income: -11006794 Open source Revenue: 6203761 Open source
20202020-07-31	Net margin	-1,286.2%	Net Income: -34232093 Open source Revenue: 2661396 Open source
20102010-07-31	Free cash flow margin	Not reported	Revenue: 1118509 Open source
20112011-07-31	Free cash flow margin	-1,448.4%	Revenue: 1172611 Open source Operating Cash Flow: -16931368 Open source Capital Expenditure: 52383 Open source
20182018-07-31	Free cash flow margin	-70,954.6%	Revenue: 3244 Open source Operating Cash Flow: -2293214 Open source Capital Expenditure: 8552 Open source
20192019-07-31	Free cash flow margin	-159%	Revenue: 6203761 Open source Operating Cash Flow: -9574193 Open source Capital Expenditure: 289917 Open source
20202020-07-31	Free cash flow margin	-230.2%	Revenue: 2661396 Open source Operating Cash Flow: -6121259 Open source Capital Expenditure: 4616 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -6.1M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-07-31	Operating cash flow	Not reported	No source recorded
20112011-07-31	Operating cash flow	-16931368	Operating Cash Flow: -16931368 Open source
20182018-07-31	Operating cash flow	-2293214	Operating Cash Flow: -2293214 Open source
20192019-07-31	Operating cash flow	-9574193	Operating Cash Flow: -9574193 Open source
20202020-07-31	Operating cash flow	-6121259	Operating Cash Flow: -6121259 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -6.1M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-07-31	Free cash flow	Unavailable	No source recorded
20112011-07-31	Free cash flow	-16983751	Operating Cash Flow: -16931368 Open source Capital Expenditure: 52383 Open source
20182018-07-31	Free cash flow	-2301766	Operating Cash Flow: -2293214 Open source Capital Expenditure: 8552 Open source
20192019-07-31	Free cash flow	-9864110	Operating Cash Flow: -9574193 Open source Capital Expenditure: 289917 Open source
20202020-07-31	Free cash flow	-6125875	Operating Cash Flow: -6121259 Open source Capital Expenditure: 4616 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

117.4% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20102010-07-31	Liabilities / assets	63.5%	Total Liabilities: 15604380 Open source Total Assets: 24575000 Open source
20112011-07-31	Liabilities / assets	170.3%	Total Liabilities: 20448501 Open source Total Assets: 12006365 Open source
20182018-07-31	Liabilities / assets	759.7%	Total Liabilities: 50191522 Open source Total Assets: 6606854 Open source
20192019-07-31	Liabilities / assets	76.3%	Total Liabilities: 37889494 Open source Total Assets: 49635991 Open source
20202020-07-31	Liabilities / assets	117.4%	Total Liabilities: 53267316 Open source Total Assets: 45382944 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.03× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20102010-07-31	Current assets / current liabilities	2×	Current Assets: 16196794 Open source Current Liabilities: 8100588 Open source
20112011-07-31	Current assets / current liabilities	0.4×	Current Assets: 3749981 Open source Current Liabilities: 9318198 Open source
20182018-07-31	Current assets / current liabilities	0.05×	Current Assets: 1188246 Open source Current Liabilities: 25229015 Open source
20192019-07-31	Current assets / current liabilities	0.03×	Current Assets: 973535 Open source Current Liabilities: 28946023 Open source
20202020-07-31	Current assets / current liabilities	0.03×	Current Assets: 1254847 Open source Current Liabilities: 41371454 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2011 2010-08-01 – 2011-07-31	−USD 21.68 million Exact value Exact value: -21675867 USD 2010-08-01 – 2011-07-31: -21675867 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2011-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -21675867 USD Concept: fundies:NetIncome Period: 2010-08-01 to 2011-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2011-07-31&surface=latest&period_type=duration&start=2010-08-01&unit=USD&dimensions= Input fundies:NetIncome: -21675867 USD (2010-08-01 to 2011-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000155479514000264/gnbt-20130731.xml#385026 Filing: 000155479514000264 The citation records this snapshot. The page link may show a newer release later.	−USD 16.93 million Exact value Exact value: -16931368 USD 2010-08-01 – 2011-07-31: -16931368 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2011-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -16931368 USD Concept: fundies:OperatingCashFlow Period: 2010-08-01 to 2011-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2011-07-31&surface=latest&period_type=duration&start=2010-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16931368 USD (2010-08-01 to 2011-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000155479514000264/gnbt-20130731.xml#453388 Filing: 000155479514000264 The citation records this snapshot. The page link may show a newer release later.	USD 52,383 Exact value Exact value: 52383 USD 2010-08-01 – 2011-07-31: 52383 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GENEREX BIOTECHNOLOGY CORP · 2011-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Capital Expenditure: 52383 USD Concept: fundies:CapitalExpenditure Period: 2010-08-01 to 2011-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ACapitalExpenditure&period=2011-07-31&surface=latest&period_type=duration&start=2010-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 52383 USD (2010-08-01 to 2011-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000155479514000264/gnbt-20130731.xml#454624 Filing: 000155479514000264 The citation records this snapshot. The page link may show a newer release later.	−USD 16.98 million Calculation and evidence -16931368 − 52383 USD Exact free cash flow: -16983751 USD 2010-08-01 – 2011-07-31: -16931368 USD · Inspect Operating Cash Flow · Source 2010-08-01 – 2011-07-31: 52383 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GENEREX BIOTECHNOLOGY CORP · 2011-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Free cash flow: -16983751 USD Concept: free-cash-flow Period: 2010-08-01 to 2011-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16931368 USD (2010-08-01 to 2011-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000155479514000264/gnbt-20130731.xml#453388 Filing: 000155479514000264 Input fundies:CapitalExpenditure: 52383 USD (2010-08-01 to 2011-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000155479514000264/gnbt-20130731.xml#454624 Filing: 000155479514000264 The citation records this snapshot. The page link may show a newer release later.
2012 2011-08-01 – 2012-07-31	−USD 9.49 million Exact value Exact value: -9490278 USD 2011-08-01 – 2012-07-31: -9490278 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2012-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -9490278 USD Concept: fundies:NetIncome Period: 2011-08-01 to 2012-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2012-07-31&surface=latest&period_type=duration&start=2011-08-01&unit=USD&dimensions= Input fundies:NetIncome: -9490278 USD (2011-08-01 to 2012-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000326/gnbt-20140731.xml#200157 Filing: 000160706215000326 The citation records this snapshot. The page link may show a newer release later.	−USD 8.04 million Exact value Exact value: -8043979 USD 2011-08-01 – 2012-07-31: -8043979 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2012-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -8043979 USD Concept: fundies:OperatingCashFlow Period: 2011-08-01 to 2012-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2012-07-31&surface=latest&period_type=duration&start=2011-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8043979 USD (2011-08-01 to 2012-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000326/gnbt-20140731.xml#895397 Filing: 000160706215000326 The citation records this snapshot. The page link may show a newer release later.	USD 2,416 Exact value Exact value: 2416 USD 2011-08-01 – 2012-07-31: 2416 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GENEREX BIOTECHNOLOGY CORP · 2012-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Capital Expenditure: 2416 USD Concept: fundies:CapitalExpenditure Period: 2011-08-01 to 2012-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ACapitalExpenditure&period=2012-07-31&surface=latest&period_type=duration&start=2011-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2416 USD (2011-08-01 to 2012-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000326/gnbt-20140731.xml#896208 Filing: 000160706215000326 The citation records this snapshot. The page link may show a newer release later.	−USD 8.05 million Calculation and evidence -8043979 − 2416 USD Exact free cash flow: -8046395 USD 2011-08-01 – 2012-07-31: -8043979 USD · Inspect Operating Cash Flow · Source 2011-08-01 – 2012-07-31: 2416 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GENEREX BIOTECHNOLOGY CORP · 2012-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Free cash flow: -8046395 USD Concept: free-cash-flow Period: 2011-08-01 to 2012-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8043979 USD (2011-08-01 to 2012-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000326/gnbt-20140731.xml#895397 Filing: 000160706215000326 Input fundies:CapitalExpenditure: 2416 USD (2011-08-01 to 2012-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000326/gnbt-20140731.xml#896208 Filing: 000160706215000326 The citation records this snapshot. The page link may show a newer release later.
2013 2012-08-01 – 2013-07-31	−USD 8.55 million Exact value Exact value: -8554322 USD 2012-08-01 – 2013-07-31: -8554322 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2013-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -8554322 USD Concept: fundies:NetIncome Period: 2012-08-01 to 2013-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2013-07-31&surface=latest&period_type=duration&start=2012-08-01&unit=USD&dimensions= Input fundies:NetIncome: -8554322 USD (2012-08-01 to 2013-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000326/gnbt-20140731.xml#200030 Filing: 000160706215000326 The citation records this snapshot. The page link may show a newer release later.	−USD 3.66 million Exact value Exact value: -3661234 USD 2012-08-01 – 2013-07-31: -3661234 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2013-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -3661234 USD Concept: fundies:OperatingCashFlow Period: 2012-08-01 to 2013-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2013-07-31&surface=latest&period_type=duration&start=2012-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3661234 USD (2012-08-01 to 2013-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000326/gnbt-20140731.xml#895212 Filing: 000160706215000326 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2014 2013-08-01 – 2014-07-31	−USD 1,417 Exact value Exact value: -1417 USD 2013-08-01 – 2014-07-31: -1417 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2014-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -1417 USD Concept: fundies:NetIncome Period: 2013-08-01 to 2014-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2014-07-31&surface=latest&period_type=duration&start=2013-08-01&unit=USD&dimensions= Input fundies:NetIncome: -1417 USD (2013-08-01 to 2014-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000445/gnbt-20150731.xml#123627 Filing: 000160706215000445 The citation records this snapshot. The page link may show a newer release later.	−USD 3.57 million Exact value Exact value: -3573625 USD 2013-08-01 – 2014-07-31: -3573625 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2014-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -3573625 USD Concept: fundies:OperatingCashFlow Period: 2013-08-01 to 2014-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2014-07-31&surface=latest&period_type=duration&start=2013-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3573625 USD (2013-08-01 to 2014-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706215000445/gnbt-20150731.xml#578101 Filing: 000160706215000445 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2014-08-01 – 2015-07-31	−USD 2.19 million Exact value Exact value: -2193358 USD 2014-08-01 – 2015-07-31: -2193358 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2015-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -2193358 USD Concept: fundies:NetIncome Period: 2014-08-01 to 2015-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2015-07-31&surface=latest&period_type=duration&start=2014-08-01&unit=USD&dimensions= Input fundies:NetIncome: -2193358 USD (2014-08-01 to 2015-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706217000021/gnbt-20160731.xml#107456 Filing: 000160706217000021 The citation records this snapshot. The page link may show a newer release later.	−USD 2.88 million Exact value Exact value: -2884736 USD 2014-08-01 – 2015-07-31: -2884736 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2015-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -2884736 USD Concept: fundies:OperatingCashFlow Period: 2014-08-01 to 2015-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2015-07-31&surface=latest&period_type=duration&start=2014-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2884736 USD (2014-08-01 to 2015-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706217000021/gnbt-20160731.xml#504826 Filing: 000160706217000021 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2015-08-01 – 2016-07-31	−USD 3.22 million Exact value Exact value: -3223109 USD 2015-08-01 – 2016-07-31: -3223109 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2016-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -3223109 USD Concept: fundies:NetIncome Period: 2015-08-01 to 2016-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2016-07-31&surface=latest&period_type=duration&start=2015-08-01&unit=USD&dimensions= Input fundies:NetIncome: -3223109 USD (2015-08-01 to 2016-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706217000349/gnbt-20170731.xml#586509 Filing: 000160706217000349 The citation records this snapshot. The page link may show a newer release later.	−USD 775,483 Exact value Exact value: -775483 USD 2015-08-01 – 2016-07-31: -775483 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2016-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -775483 USD Concept: fundies:OperatingCashFlow Period: 2015-08-01 to 2016-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2016-07-31&surface=latest&period_type=duration&start=2015-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -775483 USD (2015-08-01 to 2016-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706217000349/gnbt-20170731.xml#99848 Filing: 000160706217000349 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2016-08-01 – 2017-07-31	−USD 76.83 million Exact value Exact value: -76832599 USD 2016-08-01 – 2017-07-31: -76832599 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2017-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -76832599 USD Concept: fundies:NetIncome Period: 2016-08-01 to 2017-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2017-07-31&surface=latest&period_type=duration&start=2016-08-01&unit=USD&dimensions= Input fundies:NetIncome: -76832599 USD (2016-08-01 to 2017-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706218000361/gnbt-20180731.xml#138047 Filing: 000160706218000361 The citation records this snapshot. The page link may show a newer release later.	−USD 1.17 million Exact value Exact value: -1170349 USD 2016-08-01 – 2017-07-31: -1170349 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2017-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -1170349 USD Concept: fundies:OperatingCashFlow Period: 2016-08-01 to 2017-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2017-07-31&surface=latest&period_type=duration&start=2016-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1170349 USD (2016-08-01 to 2017-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706218000361/gnbt-20180731.xml#175053 Filing: 000160706218000361 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2017-08-01 – 2018-07-31	USD 35.95 million Exact value Exact value: 35948698 USD 2017-08-01 – 2018-07-31: 35948698 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2018-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: 35948698 USD Concept: fundies:NetIncome Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2018-07-31&surface=latest&period_type=duration&start=2017-08-01&unit=USD&dimensions= Input fundies:NetIncome: 35948698 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000047/gnbt-20191031.xml#416227 Filing: 000160706220000047 The citation records this snapshot. The page link may show a newer release later.	−USD 2.29 million Exact value Exact value: -2293214 USD 2017-08-01 – 2018-07-31: -2293214 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2018-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -2293214 USD Concept: fundies:OperatingCashFlow Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2018-07-31&surface=latest&period_type=duration&start=2017-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2293214 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000047/gnbt-20191031.xml#437555 Filing: 000160706220000047 The citation records this snapshot. The page link may show a newer release later.	USD 8,552 Exact value Exact value: 8552 USD 2017-08-01 – 2018-07-31: 8552 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GENEREX BIOTECHNOLOGY CORP · 2018-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Capital Expenditure: 8552 USD Concept: fundies:CapitalExpenditure Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ACapitalExpenditure&period=2018-07-31&surface=latest&period_type=duration&start=2017-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8552 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000047/gnbt-20191031.xml#450189 Filing: 000160706220000047 The citation records this snapshot. The page link may show a newer release later.	−USD 2.3 million Calculation and evidence -2293214 − 8552 USD Exact free cash flow: -2301766 USD 2017-08-01 – 2018-07-31: -2293214 USD · Inspect Operating Cash Flow · Source 2017-08-01 – 2018-07-31: 8552 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GENEREX BIOTECHNOLOGY CORP · 2018-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Free cash flow: -2301766 USD Concept: free-cash-flow Period: 2017-08-01 to 2018-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2293214 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000047/gnbt-20191031.xml#437555 Filing: 000160706220000047 Input fundies:CapitalExpenditure: 8552 USD (2017-08-01 to 2018-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000047/gnbt-20191031.xml#450189 Filing: 000160706220000047 The citation records this snapshot. The page link may show a newer release later.
2019 2018-08-01 – 2019-07-31	−USD 11.01 million Exact value Exact value: -11006794 USD 2018-08-01 – 2019-07-31: -11006794 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2019-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -11006794 USD Concept: fundies:NetIncome Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2019-07-31&surface=latest&period_type=duration&start=2018-08-01&unit=USD&dimensions= Input fundies:NetIncome: -11006794 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#215678 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.	−USD 9.57 million Exact value Exact value: -9574193 USD 2018-08-01 – 2019-07-31: -9574193 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2019-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -9574193 USD Concept: fundies:OperatingCashFlow Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2019-07-31&surface=latest&period_type=duration&start=2018-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9574193 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#610584 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.	USD 289,917 Exact value Exact value: 289917 USD 2018-08-01 – 2019-07-31: 289917 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GENEREX BIOTECHNOLOGY CORP · 2019-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Capital Expenditure: 289917 USD Concept: fundies:CapitalExpenditure Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ACapitalExpenditure&period=2019-07-31&surface=latest&period_type=duration&start=2018-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 289917 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#620518 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.	−USD 9.86 million Calculation and evidence -9574193 − 289917 USD Exact free cash flow: -9864110 USD 2018-08-01 – 2019-07-31: -9574193 USD · Inspect Operating Cash Flow · Source 2018-08-01 – 2019-07-31: 289917 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GENEREX BIOTECHNOLOGY CORP · 2019-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Free cash flow: -9864110 USD Concept: free-cash-flow Period: 2018-08-01 to 2019-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9574193 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#610584 Filing: 000160706220000327 Input fundies:CapitalExpenditure: 289917 USD (2018-08-01 to 2019-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#620518 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.
2020 2019-08-01 – 2020-07-31	−USD 34.23 million Exact value Exact value: -34232093 USD 2019-08-01 – 2020-07-31: -34232093 USD Inspect Net Income Open source Share or cite Citation for Net Income · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Net Income: -34232093 USD Concept: fundies:NetIncome Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ANetIncome&period=2020-07-31&surface=latest&period_type=duration&start=2019-08-01&unit=USD&dimensions= Input fundies:NetIncome: -34232093 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#215550 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.	−USD 6.12 million Exact value Exact value: -6121259 USD 2019-08-01 – 2020-07-31: -6121259 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Operating Cash Flow: -6121259 USD Concept: fundies:OperatingCashFlow Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3AOperatingCashFlow&period=2020-07-31&surface=latest&period_type=duration&start=2019-08-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6121259 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#610399 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.	USD 4,616 Exact value Exact value: 4616 USD 2019-08-01 – 2020-07-31: 4616 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Capital Expenditure: 4616 USD Concept: fundies:CapitalExpenditure Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784/explain?concept=fundies%3ACapitalExpenditure&period=2020-07-31&surface=latest&period_type=duration&start=2019-08-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4616 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#620337 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.	−USD 6.13 million Calculation and evidence -6121259 − 4616 USD Exact free cash flow: -6125875 USD 2019-08-01 – 2020-07-31: -6121259 USD · Inspect Operating Cash Flow · Source 2019-08-01 – 2020-07-31: 4616 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GENEREX BIOTECHNOLOGY CORP · 2020-07-31 GENEREX BIOTECHNOLOGY CORP (edgar:1059784) Free cash flow: -6125875 USD Concept: free-cash-flow Period: 2019-08-01 to 2020-07-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1059784?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6121259 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#610399 Filing: 000160706220000327 Input fundies:CapitalExpenditure: 4616 USD (2019-08-01 to 2020-07-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1059784/000160706220000327/gnbt-20200731.xml#620337 Filing: 000160706220000327 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

139 filings · 2,980 latest values · 2,980 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001059784, 1059784, GNBT, edgar:1059784, gnbt

Also known as GENEREX BIOTECHNOLOGY CORP

GENEREX BIOTECHNOLOGY CORP

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2019-08-01 – 2020-07-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation